Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare(R) System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
(NASDAQ:SGHT), MENLO PARK, Calif., July 30, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the results of a cost-utility analysis (CUA) assessing the cost-effectiveness of the TearCare(R) System […]